# A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

> **NCT05785819** · PHASE2 · TERMINATED · sponsor: **Veralox Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Thrombocytopenia, Immune
- Heparin Induced Thrombocytopenia

## Interventions

- **DRUG:** VLX-1005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05785819
- **Lead sponsor:** Veralox Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-26
- **Primary completion:** 2025-11-17
- **Final completion:** 2025-11-17
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Veralox Therapeutics Business Decision.
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05785819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05785819, "A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05785819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*